Christoph Gunther Stainslaw Nabzdyk, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracorporeal Membrane Oxygenation | 10 | 2023 | 1459 | 1.670 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2014 | 686 | 1.270 |
Why?
|
| Shock, Septic | 2 | 2023 | 761 | 1.070 |
Why?
|
| RNA, Small Interfering | 6 | 2014 | 3442 | 1.000 |
Why?
|
| Vasoplegia | 2 | 2022 | 15 | 0.930 |
Why?
|
| Hemostatics | 2 | 2023 | 243 | 0.770 |
Why?
|
| Mediastinal Emphysema | 1 | 2021 | 29 | 0.760 |
Why?
|
| Hypotension | 3 | 2022 | 883 | 0.730 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 1952 | 0.710 |
Why?
|
| RNA Interference | 4 | 2014 | 2846 | 0.700 |
Why?
|
| Aorta | 5 | 2014 | 2039 | 0.670 |
Why?
|
| Sepsis | 2 | 2024 | 2592 | 0.640 |
Why?
|
| Running | 1 | 2023 | 483 | 0.610 |
Why?
|
| Pneumothorax | 1 | 2021 | 379 | 0.580 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2012 | 1485 | 0.570 |
Why?
|
| Anesthesiology | 2 | 2017 | 1116 | 0.560 |
Why?
|
| Skin, Artificial | 1 | 2017 | 89 | 0.530 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2021 | 613 | 0.530 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2022 | 3620 | 0.520 |
Why?
|
| Thoracic Surgery | 1 | 2022 | 725 | 0.500 |
Why?
|
| Angioplasty | 2 | 2014 | 361 | 0.480 |
Why?
|
| Polyethyleneimine | 1 | 2014 | 67 | 0.440 |
Why?
|
| Hyaluronic Acid | 1 | 2017 | 482 | 0.430 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2013 | 11 | 0.430 |
Why?
|
| Materials Testing | 1 | 2017 | 862 | 0.430 |
Why?
|
| Enterobacter cloacae | 1 | 2013 | 22 | 0.420 |
Why?
|
| Gene Silencing | 3 | 2014 | 1513 | 0.420 |
Why?
|
| Tunica Intima | 1 | 2014 | 459 | 0.400 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2021 | 1419 | 0.390 |
Why?
|
| Hemodynamics | 2 | 2022 | 4174 | 0.390 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 318 | 0.390 |
Why?
|
| Abdominal Abscess | 1 | 2013 | 152 | 0.380 |
Why?
|
| Career Choice | 1 | 2017 | 754 | 0.380 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2013 | 192 | 0.360 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 197 | 0.360 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1617 | 0.360 |
Why?
|
| Transfection | 3 | 2014 | 5781 | 0.350 |
Why?
|
| Adipogenesis | 3 | 2017 | 358 | 0.340 |
Why?
|
| Aortic Aneurysm | 1 | 2014 | 648 | 0.330 |
Why?
|
| Ear | 1 | 2009 | 172 | 0.310 |
Why?
|
| Chemotaxis | 1 | 2011 | 598 | 0.310 |
Why?
|
| Critical Illness | 1 | 2021 | 2709 | 0.310 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1189 | 0.300 |
Why?
|
| Hydroxocobalamin | 3 | 2022 | 27 | 0.290 |
Why?
|
| Tissue Expansion | 3 | 2017 | 160 | 0.280 |
Why?
|
| Flow Cytometry | 5 | 2012 | 5870 | 0.260 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 944 | 0.250 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 2272 | 0.240 |
Why?
|
| Chondrocytes | 1 | 2009 | 791 | 0.230 |
Why?
|
| Hirudins | 2 | 2022 | 194 | 0.220 |
Why?
|
| Intubation, Intratracheal | 2 | 2021 | 1328 | 0.210 |
Why?
|
| Cell Adhesion | 4 | 2014 | 3094 | 0.210 |
Why?
|
| Hydrazones | 1 | 2022 | 102 | 0.210 |
Why?
|
| Gases | 1 | 2023 | 203 | 0.200 |
Why?
|
| Lung Transplantation | 2 | 2022 | 1305 | 0.200 |
Why?
|
| Ventilators, Mechanical | 2 | 2021 | 287 | 0.190 |
Why?
|
| Tranexamic Acid | 1 | 2023 | 176 | 0.190 |
Why?
|
| Humans | 41 | 2024 | 760621 | 0.180 |
Why?
|
| Coronary Vessels | 1 | 2012 | 3112 | 0.180 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 4433 | 0.170 |
Why?
|
| Vitamin B 12 | 1 | 2023 | 522 | 0.170 |
Why?
|
| Hyperplasia | 2 | 2014 | 1155 | 0.170 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 734 | 0.170 |
Why?
|
| Shock | 1 | 2022 | 317 | 0.170 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 546 | 0.170 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 2622 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2022 | 5125 | 0.160 |
Why?
|
| Adipocytes | 2 | 2016 | 1179 | 0.160 |
Why?
|
| Porosity | 2 | 2017 | 349 | 0.160 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2022 | 1096 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2016 | 10446 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2016 | 1112 | 0.150 |
Why?
|
| Wound Healing | 4 | 2015 | 2788 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2014 | 3517 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2024 | 1108 | 0.150 |
Why?
|
| Cell Count | 2 | 2012 | 1835 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2017 | 5870 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 566 | 0.130 |
Why?
|
| Polyethylene Terephthalates | 2 | 2014 | 115 | 0.130 |
Why?
|
| Inflammation Mediators | 3 | 2014 | 1881 | 0.130 |
Why?
|
| Smad1 Protein | 1 | 2016 | 81 | 0.130 |
Why?
|
| Neuropeptides | 2 | 2013 | 943 | 0.130 |
Why?
|
| Heparin | 1 | 2022 | 1652 | 0.120 |
Why?
|
| Health Care Sector | 1 | 2017 | 196 | 0.120 |
Why?
|
| Heart Transplantation | 2 | 2024 | 3224 | 0.120 |
Why?
|
| Methacrylates | 1 | 2015 | 109 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 6538 | 0.120 |
Why?
|
| Tissue Expansion Devices | 1 | 2016 | 156 | 0.120 |
Why?
|
| Family Practice | 1 | 2017 | 510 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 319 | 0.120 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 844 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2021 | 1166 | 0.120 |
Why?
|
| Vitamins | 1 | 2023 | 1634 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2014 | 1245 | 0.110 |
Why?
|
| Adsorption | 1 | 2014 | 198 | 0.110 |
Why?
|
| Growth Inhibitors | 1 | 2014 | 378 | 0.110 |
Why?
|
| Mitral Valve | 1 | 2021 | 1486 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 459 | 0.110 |
Why?
|
| Cell Shape | 1 | 2014 | 372 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2014 | 1446 | 0.100 |
Why?
|
| Growth Substances | 1 | 2014 | 768 | 0.100 |
Why?
|
| Patient Selection | 1 | 2024 | 4283 | 0.100 |
Why?
|
| Skin Ulcer | 1 | 2013 | 129 | 0.100 |
Why?
|
| Diabetic Neuropathies | 2 | 2013 | 406 | 0.100 |
Why?
|
| Cell-Matrix Junctions | 1 | 2011 | 21 | 0.100 |
Why?
|
| Commerce | 1 | 2017 | 605 | 0.100 |
Why?
|
| Echocardiography | 1 | 2024 | 4981 | 0.100 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 623 | 0.100 |
Why?
|
| Genetic Techniques | 1 | 2014 | 428 | 0.090 |
Why?
|
| Thrombospondins | 1 | 2011 | 193 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 755 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 1864 | 0.090 |
Why?
|
| Indicators and Reagents | 1 | 2011 | 461 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 1336 | 0.090 |
Why?
|
| Fluorescence | 1 | 2012 | 751 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2014 | 1199 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 793 | 0.080 |
Why?
|
| Atrial Function | 1 | 2009 | 99 | 0.080 |
Why?
|
| Animals | 14 | 2021 | 167963 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2011 | 617 | 0.080 |
Why?
|
| Lac Operon | 1 | 2008 | 237 | 0.080 |
Why?
|
| Thrombosis | 1 | 2022 | 3052 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 928 | 0.080 |
Why?
|
| Saphenous Vein | 1 | 2011 | 537 | 0.080 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 822 | 0.070 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 11891 | 0.070 |
Why?
|
| Endarterectomy, Carotid | 1 | 2013 | 564 | 0.070 |
Why?
|
| Leadership | 1 | 2017 | 1371 | 0.070 |
Why?
|
| Ventricular Function | 1 | 2009 | 408 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2009 | 363 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2022 | 4897 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 883 | 0.070 |
Why?
|
| Mice | 8 | 2017 | 81208 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2010 | 422 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2014 | 7850 | 0.060 |
Why?
|
| Cell Death | 1 | 2011 | 1672 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2011 | 18957 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 2640 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1588 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2014 | 3682 | 0.060 |
Why?
|
| Ischemia | 1 | 2013 | 1893 | 0.060 |
Why?
|
| Cysts | 1 | 2009 | 683 | 0.060 |
Why?
|
| Tissue Engineering | 2 | 2015 | 1870 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2009 | 1326 | 0.060 |
Why?
|
| Pandemics | 2 | 2020 | 8624 | 0.060 |
Why?
|
| Oxygen | 1 | 2015 | 4193 | 0.050 |
Why?
|
| Cattle | 1 | 2009 | 3847 | 0.050 |
Why?
|
| Hirudin Therapy | 1 | 2022 | 43 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 1913 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2009 | 1577 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 3446 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1824 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 2221 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2023 | 80372 | 0.050 |
Why?
|
| Radiography | 1 | 2013 | 6965 | 0.050 |
Why?
|
| Methylene Blue | 1 | 2021 | 157 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 2919 | 0.050 |
Why?
|
| Stents | 1 | 2013 | 3314 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2873 | 0.050 |
Why?
|
| Heart | 1 | 2014 | 4393 | 0.050 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 1223 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 1407 | 0.040 |
Why?
|
| Models, Animal | 2 | 2017 | 2117 | 0.040 |
Why?
|
| Time Factors | 5 | 2013 | 40165 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2016 | 3790 | 0.040 |
Why?
|
| Skin | 1 | 2013 | 4466 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2009 | 1915 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2014 | 12766 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2009 | 2985 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 11071 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2022 | 65017 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2009 | 1291 | 0.040 |
Why?
|
| Cytokines | 1 | 2013 | 7343 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 8056 | 0.040 |
Why?
|
| Vasodilation | 1 | 2022 | 962 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2006 | 1657 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 651 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 11903 | 0.040 |
Why?
|
| Resuscitation | 1 | 2021 | 661 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2022 | 1818 | 0.030 |
Why?
|
| Swine | 2 | 2021 | 5899 | 0.030 |
Why?
|
| Risk Factors | 2 | 2022 | 74359 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 39 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2016 | 47 | 0.030 |
Why?
|
| Disease Progression | 1 | 2013 | 13502 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 20080 | 0.030 |
Why?
|
| Apoptosis | 1 | 2011 | 9501 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2016 | 5039 | 0.030 |
Why?
|
| Respiration | 1 | 2021 | 1654 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3301 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 12103 | 0.030 |
Why?
|
| Dermis | 1 | 2016 | 202 | 0.030 |
Why?
|
| Stem Cells | 1 | 2006 | 3523 | 0.030 |
Why?
|
| Adult | 3 | 2023 | 219994 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 670 | 0.030 |
Why?
|
| Receptors, Estrogen | 2 | 2014 | 2210 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 372 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 428 | 0.030 |
Why?
|
| Child | 1 | 2021 | 79806 | 0.030 |
Why?
|
| Aged | 4 | 2021 | 169152 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 416 | 0.030 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 393 | 0.030 |
Why?
|
| Equipment Design | 1 | 2020 | 3520 | 0.020 |
Why?
|
| Cell Movement | 2 | 2016 | 5206 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 12922 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2023 | 3600 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2015 | 1850 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 606 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Seizures | 1 | 2023 | 2917 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2502 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 5889 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 1377 | 0.020 |
Why?
|
| Macrophages | 2 | 2016 | 5745 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 667 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2006 | 11481 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 461 | 0.020 |
Why?
|
| Male | 8 | 2016 | 359744 | 0.020 |
Why?
|
| Inflammation | 1 | 2009 | 10756 | 0.020 |
Why?
|
| Mast Cells | 1 | 2016 | 1390 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2008 | 777 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 420 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2008 | 575 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 22023 | 0.020 |
Why?
|
| Rabbits | 1 | 2013 | 4773 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3465 | 0.020 |
Why?
|
| Age Factors | 2 | 2014 | 18416 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 2668 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 14495 | 0.020 |
Why?
|
| Female | 5 | 2017 | 391270 | 0.020 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2006 | 141 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 2913 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 1753 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2016 | 4090 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2006 | 240 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5797 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 3484 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2010 | 790 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 956 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 2717 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 1067 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3804 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 2116 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2013 | 4122 | 0.010 |
Why?
|
| Adiposity | 1 | 2014 | 1858 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 835 | 0.010 |
Why?
|
| Lung | 1 | 2022 | 9994 | 0.010 |
Why?
|
| Glucose | 1 | 2016 | 4351 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 897 | 0.010 |
Why?
|
| Lentivirus | 1 | 2006 | 506 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2014 | 2629 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3539 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2010 | 2135 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2008 | 3105 | 0.010 |
Why?
|
| Heterozygote | 1 | 2008 | 2798 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 2057 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2008 | 1992 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 1462 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14660 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2014 | 5523 | 0.010 |
Why?
|
| Reoperation | 1 | 2010 | 4291 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 6068 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14372 | 0.010 |
Why?
|
| Middle Aged | 1 | 2013 | 220352 | 0.010 |
Why?
|
| Liver | 1 | 2014 | 7509 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54303 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4611 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4166 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20509 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 7475 | 0.010 |
Why?
|
| Adolescent | 1 | 2023 | 87810 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15840 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 12960 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 12965 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 23376 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 24123 | 0.010 |
Why?
|
| Stroke | 1 | 2013 | 9962 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18137 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 58995 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 39261 | 0.000 |
Why?
|
| Heart Failure | 1 | 2009 | 11847 | 0.000 |
Why?
|